About Medio Labs

We're building
the future of clinical diagnostic services.

Medio Labs is applying the very latest DNA engineering and sequencing technologies to revolutionize clinical diagnostic testing. The company's innovations are designed to radically expand access to the latest diagnostic technology with the goal of driving a wholesale shift from treating health crises after they occur, to regular advanced screening that prevents healthcare crises from occurring in the first place.

2018

Year we were founded

60,000+

Clinical tests processed in 2022

21+

Team members

20+

Number of diseases detected

Our approach

Impact Oriented

We are a diverse team of creative innovators who revel in making science fiction into real working technology with global impact.

At Medio Labs, we are driving a revolution in healthcare designed to massively reduce the cost of state-of-the-art clinical diagnostic testing and expand global access to quality care.

The company is applying deep expertise in clinical diagnostic assay design that leverages the latest next-generation sequencing platforms along with molecular bar codes written in RNA and attached chemically to patient samples to increase the scale and reduce the cost of quantifying multiple pathogens in every individual patient sample.

The impact of being able to test for multiple diseases that might have any number of symptoms in common using Just One Test is profound. Testing costs are dramatically reduced, Turn-around times are accelerated even in pandemic surges. Time to validated course of treatment is reduced, and patient outcomes improved.

Our values

Authenticity

We work on real problems that demand clear self knowledge, a recognition of important global challenges, and the difficulty of creating meaningful solutions that will have impact at large scale. We hold ourselves and our peers accountable.

Diversity

Complex global challenges demand complicated, multi-component and multi-approach solutions. So we emphasize diversity of thought, background, ethnicity, skills, and approach that make a whole team much more capable of generating transformative services than the cookie-cutter approaches accessible to more homogenous teams.

Excellence

When solving global challenges, there is no time to rest easy and just do more of what caused many of our problems. We have high standards of performance and self-motivation to excel, and accomplish what other consider impossible.

Transparency

We don't keep or horde knowledge for individual political power in the organization. We hold the company's collective mission as more important than individual advancement. We don't keep secrets or politics. We leave ego at the door, and work to make the best ideas happen wherever they arise. We share knowledge and training to help everyone excel, grow, and succeed.

Inspiration

There is never a dull moment or boring routine when working on global challenges. We work on problems that are so important and impactful that the reasons to get out of bed every morning are completely clear. We are working hard to improve healthcare for everyone in the world, and to offer even the poorest and most remote people access to care when before, they had none.

Service

We started Brainworks, and developed the Medio service specifically in service of global challenges that have defied easy solutions for decades. Our goal, put simply, is to use powerful new technology to save and extend lives.

Medio Labs Leadership

Our team of renowned experts offer their professional services to help your organization understand, plan for, and manage all aspects of the pandemic from general analytics of the pandemic and your organization’s pandemic response to facility risk assessment and upgrades, to pandemic operations. Medio Labs experts will work to design the best system for your needs and regularly examine your data to help you identify hot spots and minimize COVID-19 infection rates, outbreaks, and shut-downs.

Michael Boyd

Chairman

Michael is the Chairman of Medio Labs and of Jayex, LTD since its inception 11 years ago. Based in Melbourne, Jayex is publicly listed developer of next-generation patient care solutions. Mr. Boyd has been involved in the creation of new enterprises, both in the private and public sectors, for over 25 years. Mr. Boyd has been successful in developing and growing new projects in diverse areas, including healthcare, telecommunications and finance. Trained as a Charted Accountant, he was a founding Director and Chairman of Sonic Healthcare Ltd, now an ASX listed top 50 company. After leaving Sonic he started Foundation Healthcare, growing it to over 800 healthcare professionals before it was acquired by Sonic. He was also a founding partner of Iridium Satellite bringing it out from bankruptcy to now a NASDAQ listed company.

Dr. Geoffrey Ling

Independent Director

Geoff is the CEO of On Demand Pharmaceuticals, which is developing manufacturing technology for point-of-care end-to-end generic pharmaceutical production so as to liberate the USA from dependence on overseas manufacturers. He is a pharmacologist and physician, a Professor of Neurology and attending neurocritical care physician at Johns Hopkins Hospital and Professor of Neurology, Anesthesiology and Neuroscience at the Uniformed Services University of the Health Sciences who retired from the US Army as a colonel after serving 21 years of active duty including deployments in Iraq and Afghanistan. Geoffrey previously served as the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) where he led the efforts directly responsible for the creation of the Synthetic Biology industry including the founding of Moderna and BioNTech, the cornerstones of the global mRNA vaccine response to the pandemic. Prior to DARPA, Geoffrey was an Assistant Director of the White House Office of Science and Technology Policy responsible for Medical Innovation. Dr. Ling has published over 180 peer-reviewed articles, review articles and book chapters and 1 patent. He earned a B.A. degree from Washington University in Biology and History, a Ph.D. degree in Pharmacology from Cornell University and an M.D. degree from Georgetown University School of Medicine.

Dr. Phillip Alvelda

Chief Executive Officer

Phillip is an Emmy award winning scientist & teacher turned serial entrepreneur, with founding leadership stints at NASA, MicroDisplay, MobiTV, the Westminster Institute for Science Education. He has been awarded numerous industry accolades including being chosen as a World Economic Forum Technology Pioneer. He most recently served in DARPA's Biological Technologies Office that invested to create the pandemic prediction and warning systems, Moderna, and BioNTech. Prior to DARPA, Phillip was a member of NASA's technical staff where he designed sensor and computing systems that flew on the Space Shuttle, and the Gallileo, Casini, and Magellan interplanetary spacecraft. He holds numerous patents and earned his BA in Physics at Cornell Univeristy, and his MS. and Ph.D. degrees in Computer Science and Electrical Engineering at MIT's Artificial Intelligence Laboratory.

Zvi Huber

Chief Operating Officer

Zvi leads the company's operations and technology development divisions, and has a long history of advanced technology development and the rapid scaling of global technology companies. His experience spans global IoT services, where he was responsible for operations and business development for Orbcom, where his deals and deployments drove the company to its public listing. More recently, Zvi served as CTO of Sfara, an advanced automotive sensing platform built on consumer cellular phones. Prior to Sfara, Zvi served in operational and technology leadership positions at Lutron.

Shana McDevitt

Director, Clinical Genomics

Shana is the former Director of the Genomics Sequencing Facilities at U.C., Berkeley and later promoted to Director of Clinical Operations at the Innovative Genomics Institute where she ran all clinical operations for Nobel Prize winning Dr. Jennifer Doudna's laboratory, including COVID testing services for the entire UC Berkeley system. Prior, Shana ran PCR-based sequencing diagnostics at the Oakland Children's Hospital, and has built four separate whole genome sequencing SARS-CoV-2 pipelines since April 2020. She holds Master's and Bachelor's Degrees in Biomedical Sciences from UCSC.

Dr. Matthew Settles

Director of Bio-Informatics

Matt has established and led a series of state-of-the-art genomics laboratories at WA State U., U. of ID, and the U.C. Davis Genome Center. With over 70 genomics publications, , Matt is a recognized world-wide as an expert whose annual bioinformatics training program at UC Davis drew over 300 participants. He also played a pivotal role in establishing and running UC Davis’ COVID testing facility which has performed over 1 Million teststo-date. Matt hold’s a MS degree in Computer Science, and a Ph.D. in Bio-Informatics and Computational Biology from the U. of Idaho.

Quynh-Anh Mai

Assc. Director of Operations

Quynh-Anh completed her BS/MS in Molecular, Cell, and Developmental Biology in the Yanofsky Lab at UC San Diego and since then has had more than a decade of experience in synthetic biology within academia and industry, with stints at the BIOFAB at JBEI, UC Berkeley, Novozymes, and various startups in the Bay Area. She is passionate about putting her resourcefulness and creativity into developing novel process flows from conception, POC and validation, to optimization, scale-up and automation.

Dan Turner

VP of Sales & Marketing

Dan leads the company's sales and marketing divisions with a 30 year history of driving sales and marketing initiatives in advertising, technology and medical industries including WebMD, Medscape, Ignite Media Asia, and Simple Labs. Dan also designed and implemented the WebMd strategy to link patients conducting web research directly with medical professional that offered care for those very conditions. Prior, Dan worked at NASA on Atmospheric Ionizing Radiation (AIR) Analysis.

Ready to take health to the next level?